Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Cannabidiol (CBD) has garnered interest as a potential treatment for neuropathic pain, including neuralgia (nerve pain) and neuritis (nerve inflammation). There is a growing body of scientific literature investigating its analgesic and anti-inflammatory properties. Preclinical studies in animal models demonstrate that CBD can modulate pain pathways and reduce neuroinflammation, likely through effects on endocannabinoid signaling, TRPV1 receptors, and other mechanisms. Some small clinical trials and observational studies in humans suggest that CBD, often in combination with tetrahydrocannabinol (THC), may offer relief for chronic neuropathic pain syndromes. However, the evidence is limited by small sample sizes, heterogeneity in study design, varying dosages and formulations, and frequent co-administration with THC rather than CBD alone.

A 2020 review in the journal Frontiers in Pharmacology concluded that while preclinical evidence is promising, robust, large-scale clinical trials are still needed to determine the efficacy and safety of CBD for neuropathic pain, including neuralgia and neuritis. Currently, CBD is not an approved first-line therapy for these conditions, and most clinical guidelines do not recommend it outside of investigational or adjunctive use. In summary, while there is scientific rationale and preliminary evidence supporting CBD's use for neuralgia and neuritis, the quality of evidence is modest, justifying a rating of 2 out of 5.

More about Cannabidiol
More about Neuralgia and Neuritis

Other ingredients used for Neuralgia and Neuritis

Other health conditions supported by Cannabidiol

Products containing Cannabidiol